HDM1002
Sources
registry, as of 2025-03-19Stale
https://clinicaltrials.gov/study/NCT06885021
Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 780. Conditions Overweight and Obesity. A Phase 3 Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
ClinicalTrials.gov NCT06885021 protocol and results modules
registry, as of 2024-07-15Stale
https://clinicaltrials.gov/study/NCT06500299
Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults. Overall status UNKNOWN. Phases PHASE2. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 180. Conditions Overweight and Obesity. It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adults.
ClinicalTrials.gov NCT06500299 protocol and results modules
registry, as of 2026-01-09Stale
https://clinicaltrials.gov/study/NCT07331389
A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin. Overall status RECRUITING. Phases PHASE1. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 111. Conditions Overweight Subject; Healthy Subjects. The purpose of this study is to characterize the drug-drug intereaction of HDM1002 and metformin, empagliflozin, midazolam, valsartan, and warfarin in overweight/obese adult subjects. The safety and tolerability of HDM1002 with metformin, empagliflozin, midazolam, valsartan, and
ClinicalTrials.gov NCT07331389 protocol and results modules
registry, as of 2024-07-25Stale
https://clinicaltrials.gov/study/NCT06520540
HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects. Overall status UNKNOWN. Phases PHASE1. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 72. Conditions Glucagon-Like Peptide-1 Receptor Agonists. • To assess the safety of multiple oral doses of HDM1002 tablets under different titrations in Chinese overweight and obese adult subjects.
ClinicalTrials.gov NCT06520540 protocol and results modules
registry, as of 2024-09-23Stale
https://clinicaltrials.gov/study/NCT06601517
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.. Overall status UNKNOWN. Phases PHASE1. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 30. Conditions Healthy Adult Subject; Overweight Subject. The purpose of this study is to characterize the effect of HDM1002 on the PK of single dose of repaglinide, atorvastatin, digoxin and rosuvastatin in healthy adult subjects. The safety and tolerability of HDM1002 with repaglinide, atorvastatin, digoxin and rosuvastatin when given
ClinicalTrials.gov NCT06601517 protocol and results modules
publication, as of 2025-09-04Stale
https://pubmed.ncbi.nlm.nih.gov/40662378/
First-in-human study of HDM1002, a GLP-1 receptor agonist: Safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses in healthy volunteers. To evaluate the safety, tolerability, pharmacokinetics (PK) and
PMID 40662378